MELISSA NIBERT: Open Payments
NPI 1134789217 · GALLIPOLIS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,149 in 127 payments from 19 companies in 2025. Trend: 2023 $1,705 · 2024 $1,682 · 2025 $2,149
Food & beverage: $2,149
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $593 |
| Ardelyx, Inc. | 18 | $305 |
| Janssen Biotech, Inc. | 17 | $232 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $184 |
| Madrigal Pharmaceuticals | 8 | $155 |
| PFIZER INC. | 7 | $117 |
| Aimmune Therapeutics, Inc. | 4 | $67 |
| GENZYME CORPORATION | 2 | $50 |
| Travere Therapeutics, Inc. | 5 | $36 |
Products named: IBSRELA, TREMFYA, XIFAXAN, RINVOQ, ENTYVIO, REZDIFFRA, CREON, LINZESS.
Industry payments across OH — which companies pay providers there.
